Rhu-pGSN for Acute Respiratory Distress Syndrome (ARDS)

Summary

BTI-203 is a randomized, double-blind, placebo-controlled, multicenter, Phase 2 proof-of-concept (POC) study to evaluate the efficacy and safety of rhu-pGSN plus standard of care (SOC) in subjects with moderate-to-severe ARDS (P/F ratio ≤150) due to pneumonia or other infections. Potential subjects hospitalized with pneumonia or other infections are to be screened within 24 hours of diagnosis of ARDS.

Timeline

Start

2024-10-03

Primary completion

2026-10-01

Completion

2027-03-01

Drugs

Indications